Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Management

Tirzepatide Cost Effectiveness in UK T2D Care

Evaluating tirzepatide cost effectiveness reveals significant advantages over semaglutide 1 mg for patients with type 2 diabetes (T2D) inadequately controlled on metformin, based on a SURPASS-2 trial analysis. Tirzepatide (5, 10, and 15 mg) achieved superior reductions in glycated hemoglobin (HbA1c) and body weight with low hypoglycemia risk, leading to lower annual pharmacy costs per patient reaching composite endpoints like HbA1c ≤6.5% or <7.0%, weight loss ≥5-15%, and no hypoglycemia. This positions tirzepatide as a potentially cost-effective option within National Health Service (NHS) constraints.

Dominant Economics at Strict Targets

Tirzepatide cost effectiveness shines for ambitious goals from NICE, ADA, and EASD guidelines. For HbA1c ≤6.5% (48 mmol/mol), ≥15% weight loss, and no hypoglycemia, annual pharmacy costs per patient were GBP 5,650, 8,665, and 9,462 lower with tirzepatide 5, 10, and 15 mg versus semaglutide 1 mg (GBP 2023 values from NICE TA924). Tirzepatide’s higher responder rates meant lower numbers needed to treat (e.g., 2.6 for 15 mg vs. 14.3 for semaglutide), offsetting higher per-patient costs (GBP 1,200-1,591 vs. GBP 956). At population scale, a GBP 4,383,727 GLP-1 budget across 70 NHS boards treated 1,047 more patients to target with tirzepatide 15 mg. Sensitivity analyses confirmed tirzepatide 10-15 mg dominance (58-98% probability), with semaglutide viable only for lenient endpoints.